Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 19,748 Shares

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc purchased 19,748 shares of the company’s stock in a transaction that occurred on Friday, January 17th. The shares were purchased at an average price of $13.87 per share, for a total transaction of $273,904.76. Following the completion of the transaction, the director now directly owns 15,720,161 shares of the company’s stock, valued at $218,038,633.07. This represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Wednesday, January 15th, Ecor1 Capital, Llc acquired 39,029 shares of Zymeworks stock. The shares were purchased at an average cost of $14.01 per share, with a total value of $546,796.29.
• On Monday, January 13th, Ecor1 Capital, Llc bought 74,125 shares of Zymeworks stock. The stock was acquired at an average cost of $13.39 per share, for a total transaction of $992,533.75.
• On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were acquired at an average cost of $13.13 per share, for a total transaction of $2,679,806.74.
• On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The shares were acquired at an average cost of $14.07 per share, with a total value of $295,765.47.
• On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The stock was bought at an average cost of $14.78 per share, for a total transaction of $2,333,466.40.
• On Monday, December 30th, Ecor1 Capital, Llc bought 58,988 shares of Zymeworks stock. The stock was bought at an average cost of $14.47 per share, for a total transaction of $853,556.36.
• On Tuesday, December 24th, Ecor1 Capital, Llc acquired 11,958 shares of Zymeworks stock. The shares were purchased at an average cost of $14.12 per share, for a total transaction of $168,846.96.
• On Thursday, December 26th, Ecor1 Capital, Llc purchased 16,692 shares of Zymeworks stock. The shares were purchased at an average price of $14.38 per share, for a total transaction of $240,030.96.

Zymeworks Price Performance

Shares of ZYME stock traded up $0.41 during trading hours on Tuesday, reaching $14.29. 277,027 shares of the company traded hands, compared to its average volume of 516,107. The firm has a 50-day moving average price of $14.24 and a 200 day moving average price of $12.71. The company has a market cap of $984.30 million, a P/E ratio of -9.53 and a beta of 1.10. Zymeworks Inc. has a 12-month low of $7.97 and a 12-month high of $17.70.

Zymeworks (NYSE:ZYME) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $16.00 million during the quarter, compared to analyst estimates of $17.90 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company’s revenue was down 3.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.41) earnings per share. Sell-side analysts predict that Zymeworks Inc. will post -1.39 EPS for the current year.

Institutional Investors Weigh In On Zymeworks

A number of institutional investors have recently bought and sold shares of ZYME. Point72 Asset Management L.P. bought a new position in shares of Zymeworks in the second quarter worth about $1,683,000. State Street Corp boosted its stake in Zymeworks by 6.1% in the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company’s stock worth $14,706,000 after purchasing an additional 67,401 shares during the period. Barclays PLC grew its holdings in Zymeworks by 476.3% during the 3rd quarter. Barclays PLC now owns 154,384 shares of the company’s stock valued at $1,937,000 after buying an additional 127,595 shares in the last quarter. Vestal Point Capital LP raised its position in shares of Zymeworks by 39.8% during the third quarter. Vestal Point Capital LP now owns 615,000 shares of the company’s stock valued at $7,718,000 after buying an additional 175,000 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in shares of Zymeworks by 401.9% in the second quarter. Squarepoint Ops LLC now owns 73,324 shares of the company’s stock worth $624,000 after buying an additional 58,716 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Analyst Ratings Changes

ZYME has been the subject of a number of research analyst reports. Leerink Partners raised Zymeworks from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $10.00 to $25.00 in a report on Thursday, November 7th. JPMorgan Chase & Co. upgraded Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price objective for the company in a report on Monday, December 16th. Leerink Partnrs upgraded shares of Zymeworks from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 7th. Citigroup lifted their price target on shares of Zymeworks from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. Finally, Stifel Nicolaus increased their price objective on shares of Zymeworks from $21.00 to $28.00 and gave the company a “buy” rating in a research report on Monday, October 28th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.17.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.